Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
Objective: To characterize the in vitro and in vivo pharmacologic profile of UCB0022 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with reductions in…Deep Brain Stimulation in Parkinson’s disease: Challenges of a young experience in southern Morocco
Objective: The objective of our research was to describe the epidemiological, therapeutic features and effectiveness of deep brain stimulation in operated patients. To cite the…CSF biomarkers in neurodegenerative parkinsonism can distinguish between multiple system atrophy and 4-repeat tauopathies, but not between disease with Lewy bodies and multiple system atrophy
Objective: To assess the usefulness of a defined set of blood-based and cerebrospinal fluid-based biomarkers in the differential diagnosis of neurodegenerative proteinopathies. Background: The diagnostic…An AAV9 encoding human ABCD1 (SBT101) shows functional improvement following spinal cord delivery in a rodent model of adrenomyeloneuropathy
Objective: SBT101 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy candidate delivering a functional copy of the human ABCD1 gene that is in development…The noradrenergic basis of Parkinson’s tremor
Objective: Study the effect of propranolol on (stress-related increase in) tremor power and on tremor-related activity in the cerebello-thalamo-cortical (CTC) circuit in Parkinson’s (PD) patients.…Attending to Compensatory Strategies during Prolonged Walking in Parkinson Disease: A Pilot Study
Objective: 1. to compare the effects of compensatory strategies on the duration of attentive engagement during 10 min. walking, 2. to test associations between person's…Synaptic Zn2+ Contribution to Parkinson’s Disease Pathophysiology: Pharmacological & Genetic Studies in Preclinical Mouse Models
Objective: The potential involvement of synaptic Zn2+ in development of Parkinson’s disease (PD) motor symptoms and dopaminergic neurodegeneration was investigated. Background: The progressive degeneration of…No evidence for the impact of SNCA rs356219 on Parkinson’s disease progression
Objective: To replicate findings from previous studies reporting an association between the α-synuclein (SNCA) rs356219 genetic variant and progression to key outcomes in Parkinson’s disease…The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit
Objective: To assess the real-world utilization of deutetrabenazine (DTBZ) for the treatment of tardive dyskinesia (TD) or chorea associated with Huntington disease (HD) initiated by…Cortico-cortical connectivity is normalised by levodopa in tremor-dominant Parkinson’s disease
Objective: The aim of this study was to examine whether connectivity between the supplementary motor area and primary motor cortex (SMA-M1) is implicated in Parkinson’s…
- « Previous Page
- 1
- …
- 116
- 117
- 118
- 119
- 120
- …
- 153
- Next Page »